Finoriq research workspace
AEON Biopharma, Inc. (AEON) SEC Filings & Filing Highlights
AEON Biopharma, Inc. develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical. Review AEON SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
- Company
- AEON Biopharma, Inc. (AEON)
- Ticker
- AEON
- Market Cap
- $12.9M
- Latest Price
- $0.291
- Industry
- Biotech & Pharma
AEON Biopharma, Inc. (AEON) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AEON Biopharma, Inc. (AEON).
| Event | Form | Date |
|---|---|---|
| AEON Biopharma, Inc.: Shareholder voteAEON Biopharma, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”) as described in the Co... | 8-K5.07 | 2026-06-17 |
| Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESEN...Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / MAY 2026 NYSEAMERICAN: AEON © 2 0 2... | 8-K7.01 | 2026-05-14 |
| AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | 8-K2.02 | 2026-05-14 |
| The Company’s receipt of the Notice does not affect its business operations or its reporting ob...On March 31, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) received an additional written notice of non-compliance (the “Notice”) fr... | 8-K3.01 | 2026-04-03 |
| AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Ana...AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450... | 8-K2.02 | 2026-03-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.